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Abstract
Objective: Endocervical adenocarcinomas (ECA) and endometrial adenocarcinomas (EMA) are
uterine malignancies that have differing biological behaviors. The choice of an appropriate
therapeutic plan rests on the tumor's site of origin. In this study, we propose to evaluate whether
PR adds value to the performance and test effectiveness of the conventional 3-marker (ER/Vim/
CEA) panel in distinguishing between primary ECA and EMA.
Methods: A tissue microarray was constructed using paraffin-embedded, formalin-fixed tissues
from 38 hysterectomy specimens, including 14 ECA and 24 EMA. Tissue microarray (TMA)
sections were immunostained with 4 antibodies, using the avidin-biotin complex (ABC) method for
antigen visualization. The staining intensity and extent of the immunohistochemical (IHC) reactions
were appraised using a semi-quantitative scoring system.
Results: The three markers (ER, Vim and CEA) and their respective panel expressions showed
statistically significant (p < 0.05) frequency differences between ECA and EMA tumors. Although
the additional ancillary PR-marker also revealed a significant frequency difference (p < 0.05)
between ECA and EMA tumors, it did not demonstrate any supplementary benefit to the 3-marker
panel.
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Conclusion: According to our data, when histomorphological and clinical doubt exists as to the
primary site of origin, we recommend that the conventional 3-marker (ER/Vim/CEA) panel is
easier, sufficient and appropriate to use in distinguishing between primary ECA and EMA. Although
the 4-marker panel containing PR also reveals statistically significant results, the PR-marker offers
no supplemental benefit to the pre-existing 3-marker (ER/Vim/CEA) panel in the diagnostic
distinction between ECA and EMA.
Introduction
From hematoxylin and eosin (H&E) stains, it can be diffi-
cult to distinguish between pre-operative or curetting
specimens of endocervical adenocarcinomas (ECA) and
endometrial adenocarcinomas (EMA). Staging is surgical
for EMA; however, for primary ECA, staging is clinical.
Treatment protocols may differ substantially between
them [1,2].
We have already learned that certain immunohistochem-
ical markers may be helpful in distinguishing between
ECA and EMA. McCluggage, et al. (2002) proposed that a
panel of immunohistochemical stains, comprised of a 3-
marker (ER, CEA and Vim) panel, generally results in a
confident preoperative distinction between ECA and
EMA[3]. Several other studies have reported that a PR- and
p16INK4a-marker revealed a significant frequency differ-
ence (p < 0.05) between ECA and EMA. However, we were
interested to discover whether ancillary PR- or p16INK4a-
marker testing could produce any supplementary benefit
to the traditional 3-marker panel.
Our previous studies have already shown that ancillary
p16INK4a-marker testing does not add value to the tradi-
tional 3-marker (ER, CEA and Vim) or 4-marker (PR, ER,
CEA and Vim) panel in distinguishing between these 2
gynecologic malignancies (ECA vs. EMA)[4,5]. On the
other hand, it is uncertain whether the performance and
test effectiveness of the 4-marker (PR, ER, CEA and Vim)
panel is superior to the conventional 3-marker (ER, CEA
and Vim) panel in distinguishing between ECA and EMA.
In order to save on the cost and economize laboratory
resources, the purpose of this extension study was to
examine whether the additional PR-marker can provide
supplemental meaningful value to the conventional 3-
marker (ER, CEA and Vim) panel, using IHC on a TMA in
tissues from Taiwanese women [6-12].
Methods
Study materials
The study materials consisted of slides and selected forma-
lin-fixed, paraffin-embedded tissue blocks from 38 hyster-
ectomy specimens retrieved from the archives of the
Tissue Bank of the Clinical Trial Center at Chung-Shan
Medical University Hospital. These endocervical (n = 14),
and endometrial (n = 24) specimens of known origin
were collected between 2004 and 2008. Two board-certi-
fied pathologists (CP Han and LF Kok) reviewed all H&E
stained slides for these cases. A slide with a representative
tumor was selected from each case, and the tumor area of
interest was circled. The area corresponding to the selected
area on the slide was also circled on the block with an oil
marker. All the donors' tissue blocks were sent to the Bio-
Chiefdom International Co. Ltd, Taiwan for TMA slide
construction. They were cored with a 1.5-mm diameter
needle and transferred to a recipient paraffin block. The
recipient block was sectioned at 5 μm, and transferred to
silanized glass slides.
Immunohistochemical Staining
Using the avidin-biotin complex (ABC) technique, slides
were stained with monoclonal antibodies whose main
characteristics are summarized in Table 1. Formalin-fixed,
paraffin-embedded tissue array specimens with 1.5-mm, 5
μm individual cores, were deparaffinized in xylene, rehy-
drated through serial dilutions of alcohol, and washed in
PBS (pH 7.2). The pH 7.2 PBS buffer was used for all sub-
sequent washes. Slides were stained with the following
monoclonal antibodies: progesterone receptor (PR)
(NCL-PGR-312, Leica Microsystems), 1:100 dilution;
estrogen receptor (ER) (NCL-L-ER-6F11, Leica Microsys-
tems), 1:100 dilution; vimentin (Vim) (NCL-L-VIM-V9,
Leica Microsystems), 1:400 dilution; and carcinoembry-
onic antigen (CEA) (NCL-L-CEA-2, Leica Microsystems),
1:100 dilution. (Table 1) Negative controls were obtained
Table 1: Antibodies used in this study
Antigen Clone Supplier Dilution Antigen retrieval
PR Mouse Monoclonal, 16 Leica Microsystems 1:100 citrate
ER Mouse Monoclonal, 6F11 Leica Microsystems 1:100 citrate
Vim Mouse monoclonal, V9 Leica Microsystems 1:400 citrate
CEA Mouse monoclonal, 12-140-10 Leica Microsystems 1:100 trypsinJournal of Translational Medicine 2009, 7:37 http://www.translational-medicine.com/content/7/1/37
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by excluding the primary antibody. Appropriate positive
controls were applied. The slides were mounted for exam-
ination and the images captured by the Olympus BX51
microscopic DP71 Digital Camera System for study com-
parison.
Scoring of immunostaining
In this study, the TMA slides were simultaneously
reviewed and scored by the two aforementioned patholo-
gists using a two-headed microscope. Since both nucleic
and cytoplasmic IHC scoring algorithms had not been
optimized and standardized, all PR, ER, Vim and CEA
expressions were interpreted using a German semi-quan-
titative scoring system for assessing the staining intensity
and extent[13]. The intensity of marker expression was
quantified using the following scores: 0 = negative, 1 =
weakly positive, 2 = moderately positive, 3 = strongly pos-
itive. The extent of marker expression was quantified by
evaluating the percentage of the positive staining areas in
relation to the whole cancer area in the core. A score of 0
points was given for 0% reactivity, 1 point was assigned
for 1–10% reactivity, 2 points were assigned for 11–50%
reactivity, 3 points were assigned for 51–80% reactivity,
and 4 points were assigned for 81–100% reactivity. The
final immunoreactive score was determined by multiply-
ing the positive intensity and the positive extent scores,
yielding a range from 0 to 12. The threshold for differen-
tiating between a final positive and negative immunos-
taining was set at 4 for interpretation. This optimal cut-off
value, for this study, was determined by using the receiver
operating characteristic (ROC) curve analysis (Metz,
1978; Zweig & Campbell, 1993)[14,15]. The results can
be expressed by dividing cases into groups with scores of
0 to 3 (essentially negative) and 4 to 12 (at least moder-
ately positive in at least 11–50% of cells). This method of
assessment has been widely accepted and used in previous
studies [16-20].
Statistical analysis
A chi-squared test or Fisher exact test was performed to
test the frequency difference of immunostaining (positive
vs. negative) between each IHC biomarker and the two
adenocarcinomas. A score of 0 to 3 was classified as nega-
tive, and a score of 4–12 was classified as positive. A
Mann-Whitney U-test was used to analyze the immunos-
taining raw scores between the two adenocarcinomas,
given the lack of normally distributed IHC scores. To dis-
tinguish between primary ECA and EMA, the sensitivity
and specificity of EC-type and EM-type immunoprofiles
were compared. Sensitivity was defined as the ratio of
accurate expression of a typical immunoprofile type
among the primary adenocarcinoma of origin. Specificity
was defined as the number of tissues that lack typical
immunoprofile type expression over the number of tis-
sues that were not actually the primary adenocarcinoma
of origin[21]. All analyses were performed using SPSS sta-
tistical software (SPSS, Inc., Chicago, IL). All tests were 2-
sided and the significance level was 0.05.
Results
H&E and immunoreactivities for PR, ER, Vim and CEA
can be seen in ECA and EMA. (Figure 1) The IHC findings
are summarized in Table 2. Using a score of  4 points as
a cutoff, all of the 4 markers showed a significant fre-
quency difference between ECA and EMA tissue immu-
nostainings. The PR-marker stained positive in 3 out of 14
(21.4%) ECA tumors with a median staining score of 0
and range of 0–9. The PR-marker stained positive in 14
out of 24 (58.3%) EMA tumors (p = 0. 027) with a median
staining score of 5.00 and a range of 0–12 (p = 0.002). The
ER-marker stained positive in 2 out of 14 (14.3%) ECA
tumors with a median staining score of 0.50 and range of
0–6. The ER-marker stained positive in 18 out of 24
(75.0%) EMA tumors (p < 0.001) with a median staining
score of 6.00 and a range of 0–12 (p < 0.001). The Vim-
marker stained positive in 1 out of 14 (7.1%) ECA tumors
with a median staining score of 0.00 and a range of 0–6.
The Vim-marker stained positive in 16 out of 24 (66.7%)
EMA tumors (p < 0.001) with a median staining score of
6.00 and a range of 0–12 (p < 0.001). The CEA-marker
stained positive in 10 out of 14 (71.4%) ECA tumors with
a median staining score of 5.00 and a range of 1–12. The
CEA-marker stained positive in 4 out of 24 (16.7%) EMA
tumors (p = 0.001), with a median staining score of 2.00
and a range of 0–9 (p < 0.001). These results found in Tai-
wanese women correspond with previous reports on Cau-
casian women[4,5,7-12].
We know that a typical EC-type immunoprofile staining
pattern consists of PR-/ER-/Vim-/CEA+, and a typical EM-
type immunoprofile staining pattern consists of PR+/ER+/
Vim+/CEA-. In addition to the typical expression patterns
of the ECA and EMA immunoprofiles, there are several
other non-typical expression patterns for this 4-marker
immunoprofile, as shown in Tables 3 and 4. When using
the conventional 3-marker panel as a tool for the diagnos-
tic distinction between ECA and EMA, there were 8 typical
EC-type (ER-/Vim-/CEA+) expressions in the 14 primary
ECA (57.14%), (Table 3) and 11 typical EM-type (ER+/
Vim+/CEA-) expressions in the 24 primary EMA
(45.83%). (Table 4) However, after adding the PR-marker
to the traditional 3-marker (ER/Vim/CEA) panel, there
still remained the same 8 typical EC-type (PR-/ER-/Vim-/
CEA+) expressions in the 14 primary ECA (57.14%),
(Table 3) and 9 typical EM-type (PR+/ER+/Vim+/CEA-)
expressions in the 24 primary EMA (37.50%). (Table 4)
Table 5 presents the comparisons of the test effectiveness
and performance between the 3-marker (ER/Vim/CEA)
and 4-marker (PR/ER/Vim/CEA) panels with typical EC-Journal of Translational Medicine 2009, 7:37 http://www.translational-medicine.com/content/7/1/37
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type or typical EM-type in diagnostically distinguishing
between 14 ECA and 24 EMA.
Discussion
Distinguishing between primary ECA and EMA before
deciding the patient treatment plan is clinically impor-
tant. Diagnostic difficulties may occur with some hyster-
ectomy specimens when the tumor involves both the
uterine endometrium and the endocervix. During preop-
erative assessment, there have been difficulties determin-
ing the primary tumor site using H&E alone. This study
not only investigated the expression of 4 individual mark-
ers (PR, ER, Vim and CEA), but also evaluated whether
panel performance and test effectiveness benefit from
adding the PR-marker to the conventional 3-marker (ER/
Vim/CEA) panel using IHC on a TMA techniques. This
data will help in the referral and management of ECA and
EMA cases worldwide.
There were some times when we inspected the surgical
specimens during (or after) the staging procedure and
found that the tumors involved both the endometrium
and the endocervix. On other occasions, we obtained
specimens from the biopsy of both sites of the lesions pre-
operatively or by fractional dilation and curettage (D&C),
consisting of endocervical and endometrial curettage,
which is already used as a classic standard procedure to
diagnostically distinguish between EMA with (or without)
cervical involvement and ECA with (or without) endome-
trial involvement. If the gross examination of hysterec-
tomy specimens reveals indistinguishable primaries or the
H&E histomorphology at these two adjacent lesions is
similar, IHC with the traditional 3-marker (ER/Vim/CEA)
or 4-marker (PR/ER/Vim/CEA) panel can be of great
assistance in making the diagnostic distinction between
ECA and EMA. In the 3-marker panel (ER/Vim/CEA), ECA
tend to be ER-/Vim-/CEA+ and EMA tend to be ER+/
Vim+/CEA-. Moreover, in the 4-marker panel (PR/ER/
Vim/CEA), ECA tend to be PR-/ER-/Vim-/CEA+ and EMA
tend to be PR+/ER+/Vim+/CEA-[4,5,7-12]. Within a
tumor immunoprofile of either ECA or EMA, unexpected
"aberrant" expressions may occur with any one or more of
the 3- or 4-marker panels discussed. In this study, the IHC
results of all the 4 individual markers (PR, ER, Vim and
CEA), as well as their respective 3-marker (ER/Vim/CEA)
or 4-marker (PR/ER/Vim/CEA) panels, showed significant
differences in expression frequencies between the two
types of adenocarcinomas (ECA vs. EMA).
We used the immunohistochemistry (IHC) on a tissue
microarray (TMA) technique to investigate multiple spec-
imens simultaneously in this extension study. This
approach results in a dramatic reduction of time and cost
compared with conventional histopathologic research
techniques. TMA has become a popular tool for tissue-
based research because it allows for the massive accelera-
tion of studies correlating molecular in situ findings with
clinico-pathological information. TMA has become spe-
cifically useful in surveys of tumor populations where it
can be utilized to analyze the functions of specific markers
or panels in neoplastic human tissues in both a compre-
hensive and efficient manner. On the other hand, the lim-
itation of TMAs seems to be the insufficiency to
demonstrate heterogeneity of the tumor because of the
small size of tissue used; however, sampling with optimal
cores in TMA was enough to show accuracies compared
H&E and immunohistochemical stains for PR, ER, Vim and CEA identified in endocervical adenocarcinomas (ECA) versus  endometrial adenocarcinomas (EMA) Figure 1 (see previous page)
H&E and immunohistochemical stains for PR, ER, Vim and CEA identified in endocervical adenocarcinomas 
(ECA) versus endometrial adenocarcinomas (EMA). A1, B1, C1, D1 and E1 came from one case with ECA, while A2, 
B2, C2, D2 and E2 came from another case with EMA. (A1) Adenocarcinoma of endocervix, endocervical type, H&E stain. (A2) 
Adenocarcinoma of endometrium, endometroid type, H&E stain. (B1) Progesterone receptor (PR) IHC score of ECA tumor 
cells was 0. (B2) Progesterone receptor (PR) IHC score of EMA tumor cells was 12. (C1) Estrogen receptor (PR) IHC score of 
ECA tumor cells was 0. (C2) Estrogen receptor (PR) IHC score of EMA tumor cells was 12. (D1) Vimentin IHC score of ECA 
tumor cells was 0. (D2) Vimentin of EMA tumor cells IHC score was12. Internal controls of stroma tissues showed strong pos-
itive result in both D1 and D2. (E1) Carcinoembryonic antigen (CEA) IHC score of ECA tumor cells was 12. (E2) Carcinoem-
bryonic antigen (CEA) IHC score of EMA tumor cells was 2. (All were viewed at 400X magnification).
Table 2: Immunohistochemical staining results (N: sample size)
ECA (N = 14) EMA (N = 24) p-value
PR Score 0–3 11 (78.6%) 10 (41.7%) .027a
Score 4–12 3 (21.4%) 14 (58.3%)
Median (Range) 0.00 (0–9) 5.00 (0–12) .002b
ER Score 0–3 12 (85.7%) 6 (25.0%) < 0.001a
Score 4–12 2 (14.3%) 18 (75.0%)
Median (Range) 0.50 (0–6) 6.00 (0–12) < 0.001b
Vim Score 0–3 13 (92.9%) 8 (33.3%) < 0.001a
Score 4–12 1 (7.1%) 16 (66.7%)
Median (Range) 0.00 (0–6) 6.00 (0–12) < 0.001b
CEA Score 0–3 4 (28.6%) 20 (83.3%) .001a
Score 4–12 10 (71.4%) 4 (16.7%)
Median (Range) 5.00 (1–12) 2.00 (0–9) < 0.001b
1. Note: the a is chi-square test with continuity correction or Fisher's 
exact test, the b is the Mann-Whitney U test using exact significance
2. Using a score of  4 points as a cutoff, the immunostains are 
defined as "negative" for scores from 0 to 3, and "positive" for scores 
from 4 to 12 points.Journal of Translational Medicine 2009, 7:37 http://www.translational-medicine.com/content/7/1/37
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with whole mount sections. Studies have shown that
increasing the number of cores results in only a slightly
higher rate of validity and the noteworthy shortcomings
of extra labor for constructing arrays, sample interpreta-
tion and data processing[22,23]. All 38 specimens were
validated in this study.
IHC is no longer a qualitative immunoassay used only in
research, but it is being increasingly employed as a semi-
quantitative or quantitative mode for the assessment of
the presence of some therapeutic and prognostic biomar-
kers. Despite lacking a clear definition, many published
papers have referred to the German Immunohistochemi-
cal Scoring System, as well as the term "semiquantative"
to depict the scoring system for IHC interpretation. In fact,
the "semiquantitative" scoring mechanism has generally
been defined as the final immunoreactive score (IRS) is
equal to the percentage of the extent of "quantitative" pos-
itive areas multiplied by the "qualitative" average of stain-
ing intensity. This "semiquantitative" scoring method has
been reproduced and widely used in many laborato-
ries[13,16,24-28].
There are a variety of IHC scoring methods including com-
puter-based plans presented in literature, and there still
seems to be no generally accepted protocol in research
laboratories and clinical practices for rating and scoring
immunostaining results. Comparing commercially
derived computer-based programs with the conventional
analyses by pathologists, there is still a lack of optimized
and standardized IHC scoring algorithms. As a result, the
objective accuracy did not significantly improve the clini-
cal outcome measures. This study uses a widely accepted
semi-quantitative scoring system for interpretation[13,16-
20,24-28].
In other studies, it has been reported that IHC stained pos-
itive for the PR-marker in 89–96% of EMA, in contrast to
4–21% of ECA. IHC stained positive for the ER-marker in
67–97% of EMA, in contrast to 4–20% of ECA. IHC
stained positive for the Vim-marker in 62–93% of EMA, in
contrast to 7–14% of ECA; and IHC stained positive for
the CEA-marker in 14–27% of EMA, in contrast to 62–
93% of ECA.[4,5,7-12] In addition, we have already
reported that when using the 3-marker (ER/Vim/CEA)
panel, IHC stained positive for the ER-marker in 75.0% of
EMA, in contrast to 14.3% of ECA. IHC stained positive
for the Vim-marker in 66.7% of EMA, in contrast to 7.1%
of ECA; and IHC stained positive for the CEA-marker in
16.7% of EMA, in contrast to 71.4% of ECA in our previ-
Table 3: Panel performance for the diagnosis of ECA (sample size 14)
ER > 3 Vim > 3 CEA > 3 PR > 3 number % with this panel
- - - - 2 14.29%
-- -+ 1 7 . 1 4 %
*- - + - 8 57.14%
-+ ++1 7 . 1 4 %
+- - +1 7 . 1 4 %
+- + -1 7 . 1 4 %
1. -: score negative, +: score positive
2. Despite PR, panel expression with ER-/Vim-/CEA+ in mark-* was defined as a typical EC-type immunoprofile. Others were defined as non-typical 
EC-type immunoprofiles.
3. All 8 cases with typical EC-type (*) immunoprofile expression also exhibited PR (-).
Table 4: Panel performance for the diagnosis of EMA (sample size 24)
ER > 3 Vim > 3 CEA > 3 PR > 3 number % with this panel
-- - -2 8 . 3 3 %
-- +-1 4 . 1 7 %
- + - - 3 12.50%
+- - -2 8 . 3 3 %
+- - +2 8 . 3 3 %
+- ++1 4 . 1 7 %
*+ + - - 28 . 3 3 %
*+ + - + 9 37.50%
++ + +2 8 . 3 3 %
1. -: score negative, +: score positive
2. Despite PR, panel expressions with ER+/Vim+/CEA- in mark-* were defined as typical EM-type immunoprofiles. Others were defined as non-
typical EM-type immunoprofiles.
3. 11 cases with typical EM-type (*) immunoprofile expression also exhibited PR (+) in 9 cases, and PR (-) in 2 cases.Journal of Translational Medicine 2009, 7:37 http://www.translational-medicine.com/content/7/1/37
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ous study[4,5]. In this study, we also found that IHC
stained positive for the PR-marker in 58.3% of EMA, in
contrast to 21.4% of ECA. The IHC results of these 4 indi-
vidual markers and their respective 4-marker panel (PR/
ER/Vim/CEA) revealed a significant diagnostic distinction
between these 2 gynecologic malignancies (ECA vs. EMA)
in this series of 14 cases of ECA and 24 cases of EMA.
McCluggage, et al. (2002) has already proposed that the
conventional IHC 3-marker panel (ER, Vim and CEA)
generally allows for a confident preoperative distinction
between a primary endometrial and endocervical adeno-
carcinoma[3]. In this study, our purpose was to assess
whether the 4-marker (PR/ER/Vim/CEA) panel contain-
ing PR could provide a more favorable performance than
the conventional 3-marker (ER/Vim/CEA) panel in distin-
guishing between primary ECA and EMA.
In accordance with previous reports, we defined the typi-
cal EC-type immunoprofile as ER-/Vim-/CEA+, and the
typical EM-type immunoprofile as ER+/Vim+/CEA-, using
the conventional 3-marker (ER/Vim/CEA) panel. We also
defined the typical EC-type immunoprofile as PR-/ER-/
Vim-/CEA+, and the typical EM-type immunoprofile as
PR+/ER+/Vim+/CEA-, using the 4-marker (PR/ER/Vim/
CEA) panel[4,5,7-12].
In this study, with regard to the typical immunoprofiles in
the conventional 3-marker (ER/Vim/CEA) panel, the sen-
sitivity and negative predictive value (NPV) were 57.1%
and 79.3% in ECA and 45.8% and 51.9% in EMA. How-
ever, considering the 4-marker (PR/ER/Vim/CEA) panel,
the sensitivity and the negative predictive value (NPV)
remained at 57.1% and 79.3% in ECA, but decreased to
37.5% and 48.3% in EMA with the typical EM-type immu-
noprofile. All these results indicated a high false-negative
rate. If the staining results do not match up with the typi-
cal EC-type or EM-type immunoprofile, despite the PR-
staining result, there is a high probability that the corre-
sponding ECA or EMA tumor diagnosis will be doubtful
and inconclusive. The low sensitivity and NPV of both
panels are the limiting factors for the application of either
the 3 or 4-marker immunoprofiles as a screening tool for
ECA and EMA.
Moreover, regarding the 3-marker (ER/Vim/CEA) panel,
the specificity and positive predictive value (PPV) were
95.8% and 88.9% in ECA and 100% and 100% in EMA.
However, considering the 4-marker panel (PR/ER/Vim/
CEA), the specificity and positive predictive value (PPV)
remained the same at 95.8% and 88.9% in ECA and 100%
and 100% in EMA. All these results indicated a low false-
positive rate. If the staining result matches up with the
typical EC-type or EM-type immunoprofile, despite the PR
staining result, there is a high probability that the corre-
sponding ECA or EMA tumor diagnosis will be accurate
and conclusive. The high specificity and PPV of both pan-
els are the promising factors for the application of either
the 3 or 4-marker immunoprofiles as a confirmatory tool
for the diagnosis of ECA and EMA.
Above all, accuracy means the degree of veracity. When
using both 3-marker and 4-marker panels with typical EC-
type (ER-/Vim-/CEA+ or PR-/ER-/Vim-/CEA+) immuno-
profiles in definitively diagnosing primary ECA, both pan-
els had the same accuracy rate (80.0% vs. 80.0%). On the
other hand, when using both 3-marker and 4-marker pan-
els with typical EM-type (ER+/Vim+/CEA- or PR+/ER+/
Vim+/CEA-) immunoprofiles in definitively diagnosing
primary EMA, the 3-marker panel had only a slightly
higher accuracy rate compared with the 4-marker panel
(68.6% vs. 65.7%).
Table 5: Comparisons of the test effectiveness and performance between the 3-marker and 4-marker panels with typical EC type, 
typical EM type, typical EC type + PR (-) and typical EM type + PR (+) expressions in 14 ECA and 24 EMA
ECA EMA
Panel compositions 3-marker
Typical EC type
4-marker
Typical EC type + PR(-)
3-marker
Typical EM type
4-marker
Typical EM type + PR(+)
Sensitivity
(95% CI)
0.571 (0.414, 0.729) 0.571 (0.414, 0.729) 0.458 (0.296, 0.621) 0.375 (0.217, 0.533)
Specificity
(95% CI)
0.958 (0.895, 1.000) 0.958 (0.895, 1.000) 1.000 (1.000, 1.000) 1.000 (1.000, 1.000)
Positive predictive value (95% CI) 0.889 (0.789, 0.989) 0.889 (0.789, 0.989) 1.000 (1.000, 1.000) 1.000 (1.000, 1.000)
Negative predictive value (95% CI) 0.793 (0.664, 0.922) 0.793 (0.664, 0.922) 0.519 (0.355, 0.682) 0.483 (0.320, 0.646)
Accuracy (95% CI) 0.80 (0.667, 0.933) 0.80 (0.667, 0.933) 0.686 (0.534, 0.837) 0.657 (0.502, 0.812)
1. -: negative score, +: positive score, 95% CI: 95% confidence interval.
2. Typical EC-type: immunoprofile expression with ER-/Vim-/CEA+
3. Typical EM-type: immunoprofile expression with ER+/Vim+/CEA-
4. PR (-) attributable to typical EC-type panel and PR (+) attributable to typical EM type panel.Journal of Translational Medicine 2009, 7:37 http://www.translational-medicine.com/content/7/1/37
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It has been reported that most endocervical adenocarcino-
mas (ECAs) contain high-risk human papillomavirus
(HPV) DNA, whereas endometrial adenocarcinomas
(EMAs) rarely do. However, HPV data was not included in
this report because we have already shown that the expres-
sion of p16INK4a protein is significantly higher in endocer-
vical adenocarcinomas than in endometrial
adenocarcinomas, and the p16INK4a marker seems to be a
sensitive surrogate for the presence of HPV infection[29].
In this study, we did not include the p16INK4a-marker as an
essential constituent in the panel along with ER/PR/Vim/
CEA because our previous report demonstrated that add-
ing the p16INK4a to the conventional 3-marker (ER/Vim/
CEA) or 4-marker (PR/ER/Vim/CEA) panel did not
improve the panel performances in the diagnostic dis-
crimination between ECA and EMA using the same IHC
on a TMA techniques[4,5]. In addition, the interpretation
of IHC data with p16INK4a staining results is complicated
because of the unclear biological significance of cytoplas-
mic staining and the lack of a universally accepted algo-
rithm in the scoring methodology[30,31]. Some
researchers regard cytoplasmic reactivity as an unex-
pected, unspecific event and consider nucleic p16INK4a
labeling in tumor cells to be only positive[16,32-35]. Oth-
ers have stated, on the contrary, that both nucleic and
cytoplasmic immunoreactivities in tumor cells are charac-
teristic and are indeed due to p16INK4a expression [36-40].
The knowledge about the functional meaning of cytoplas-
mic p16INK4a expression is still limited and further large-
scale studies are needed on various human tissues and
tumors.
In summary, it is known that each of the four monoclonal
antibodies directed against PR, ER, Vim, and CEA as well
as a pre-existing panel, comprised of either 3 members
(ER, Vim, CEA) or 4 members (PR, ER, Vim, CEA), could
help in distinguishing between adenocarcinomas of
endocervical origin and adenocarcinomas of endometrial
origin. This study has demonstrated similar results to
other studies in that a typical EC-type immunoprofile
tends to be ER-/Vim-/CEA+ in ECA, whereas a typical EM-
type immunoprofile tends to be ER+/Vim+/CEA- in EMA.
The PR-marker tends to show negative expression in ECA,
but positive expression in EMA. After assessing the panel
performance and test effectiveness for sensitivity, specifi-
city, NPV, PPV and accuracy of both 3- and 4-marker pan-
els, we found that there was no supplemental benefit of
adding the PR-marker to the conventional 3-marker (ER/
Vim/CEA) panel in distinguishing between ECA and EMA.
Despite the limited number of cases, the data provides sig-
nificant and valuable references for further investigation
to determine other useful immunoprofiles or panels that
will definitively distinguish between ECA and EMA.
Conclusion
Distinguishing between ECA and EMA can often be
accomplished by routine gross and histological examina-
tions, but some cases reveal tumors with undetermined
origins or overlapping histomorphologic features. An
accurate diagnosis may require the use of ancillary IHC
stains. Data from this TMA study provides valuable refer-
ences of consistency between Taiwanese and Caucasian
women. We found that the 3-marker (ER/Vim/CEA) panel
can sufficiently provide a more advantageous, cost-effec-
tive, and easier means for appropriately distinguishing
between ECA and EMA. Although the 4-marker (PR/ER/
Vim/CEA) panel also reveals statistically significant
results, it is a waste of resources. Based on our data, we
found that adding the PR-marker offers no supplemental
benefit to the pre-existing 3-marker (ER/Vim/CEA) panel
in the diagnostic distinction between ECA and EMA.
Therefore, we still recommend the conventional 3-marker
panel with ER, Vim and CEA as sufficient, appropriate and
useful in distinguishing the difference in origin between
ECA and EMA.
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